Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Condition(s):Non-muscle Invasive Bladder Cancer; HER-2 Protein OverexpressionLast Updated:January 2, 2024Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Non-muscle Invasive Bladder Cancer; HER-2 Protein OverexpressionLast Updated:January 2, 2024Not yet recruiting
Condition(s):Breast Cancer; Gastric/Gastroesophageal Junction CancerLast Updated:November 17, 2021Unknown status
Condition(s):Gynecological MalignancyLast Updated:December 18, 2023Recruiting
Condition(s):Advanced Solid TumorLast Updated:October 24, 2023Completed
Condition(s):Solid TumorsLast Updated:February 15, 2024Recruiting
Condition(s):Gastric CancerLast Updated:December 18, 2023Recruiting
Condition(s):Breast CancerLast Updated:April 14, 2022Unknown status
Condition(s):Gastric Cancer; Gastroesophageal Junction AdenocarcinomaLast Updated:December 14, 2023Recruiting
Condition(s):Cervical CancerLast Updated:February 28, 2024Recruiting
Condition(s):Ovarian CancerLast Updated:April 2, 2021Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.